Dr. Mingxu is a Senior Technical Advisor in research and development, SinoVet Inc. Prior to May 2016 he worked in virology bioprocess, R&D., Pfizer Inc., in Michigan. He was responsible for validation of vaccine bioprocess development, cell suspension technique and technical transfer. He received Pfizer Individual Performance Awards in 2010 to 2015 since joining Pfizer Inc. in 2009. Prior to joining Pfizer, Mingxu has 12 plus years of vaccine research and development experience in Merck Inc. He was responsible for project proposals, experimental design, data analysis, study reports, vaccine development and license application. Mingxu holds a doctoral degree in medicine and a master degree in medical virology from China Medical University. He taught medical students in Microbiology and Immunology as a tenure-track faculty position for 11 years. He spent 8 years as a post-doctoral research fellow in medical schools, medical centers and government laboratories (CDC) in Italy, Canada and the United States. He won National Research Awards, National Institutes of Health (NIH) during his post-doctoral years. Mingxu was the first to discover “Human herpes viruses -6 infection in heart transplantation recipients” and “The impact of HIV and EBV co-infection in human T and B cells”. He wrote a great deal and currently served as a member of editorial board and peer reviewer for several medical journals. Mingxu is a full Member of American Society for Microbiology since 1992.
His research interest includes Microbiology and Immunology